# Retatrutide Retatrutide has 33 registered human trials. It is marketed for 3 different uses. **In short** - 33 registered human trials exist for Retatrutide. - Retatrutide is not FDA-approved for any use. - What has actually been studied: obesity, type 2 diabetes, overweight. - Last checked against ClinicalTrials.gov on 2026-07-27. ## What it is sold for - Weight loss - Blood sugar control - Metabolic health ## What has actually been tested - Obesity - Type 2 Diabetes - Overweight - Obstructive Sleep Apnea - Healthy - Cardiovascular Diseases - Chronic Low Back Pain (CLBP) - Metabolic Dysfunction-Associated Steatotic Liver Disease - Osteo Arthritis Knee - Renal Insufficiency - Diabetes Mellitus, Type 2 - Atherosclerotic Cardiovascular Disease (ASCVD) - Chronic Kidney Disease (CKD) - Body Composition - Hepatic Insufficiency - Diabetes Mellitus - Insulin Sensitivity - Overweight or Obesity - CKD - Diabetes Type 2 - Osteoarthritis, Knee - Type 2 Diabetes Mellitus ## Every trial on record | Trial ID | Title | Condition | Phase | Status | Enrolled | |---|---|---|---|---|---| | [NCT06313528](https://clinicaltrials.gov/study/NCT06313528) | A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943 | Obesity | Phase 1 | COMPLETED | 85 | | [NCT05929079](https://clinicaltrials.gov/study/NCT05929079) | A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight | Type 2 Diabetes, Obesity | Phase 3 | ACTIVE_NOT_RECRUITING | 1000 | | [NCT03841630](https://clinicaltrials.gov/study/NCT03841630) | A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants | Healthy | Phase 1 | COMPLETED | 45 | | [NCT07467447](https://clinicaltrials.gov/study/NCT07467447) | Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight | Obesity | Phase 2 | RECRUITING | 300 | | [NCT05882045](https://clinicaltrials.gov/study/NCT05882045) | A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease | Obesity, Cardiovascular Diseases | Phase 3 | ACTIVE_NOT_RECRUITING | 1946 | | [NCT07035093](https://clinicaltrials.gov/study/NCT07035093) | A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain | Obesity, Overweight | Phase 3 | ACTIVE_NOT_RECRUITING | 586 | | [NCT05445232](https://clinicaltrials.gov/study/NCT05445232) | A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants | Obesity | Phase 1 | COMPLETED | 32 | | [NCT07165028](https://clinicaltrials.gov/study/NCT07165028) | A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Metabolic Dysfunction-Associated Steatotic Liver Disease | Phase 3 | RECRUITING | 4500 | | [NCT05931367](https://clinicaltrials.gov/study/NCT05931367) | A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee | Obesity, Overweight | Phase 3 | COMPLETED | 445 | | [NCT06003465](https://clinicaltrials.gov/study/NCT06003465) | A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices | Healthy | Phase 1 | COMPLETED | 57 | | [NCT05611957](https://clinicaltrials.gov/study/NCT05611957) | A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function | Healthy, Renal Insufficiency | Phase 1 | COMPLETED | 29 | | [NCT04143802](https://clinicaltrials.gov/study/NCT04143802) | A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM) | Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 72 | | [NCT06662383](https://clinicaltrials.gov/study/NCT06662383) | A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | Obesity | Phase 3 | ACTIVE_NOT_RECRUITING | 800 | | [NCT04867785](https://clinicaltrials.gov/study/NCT04867785) | A Study of LY3437943 in Participants With Type 2 Diabetes | Type 2 Diabetes | Phase 2 | COMPLETED | 281 | | [NCT06383390](https://clinicaltrials.gov/study/NCT06383390) | The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | Phase 3 | ACTIVE_NOT_RECRUITING | 10000 | | [NCT06260722](https://clinicaltrials.gov/study/NCT06260722) | Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) | Diabetes Mellitus, Type 2 | Phase 3 | ACTIVE_NOT_RECRUITING | 1250 | | [NCT07226947](https://clinicaltrials.gov/study/NCT07226947) | Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment | Obesity, Body Composition | Not phased | RECRUITING | 100 | | [NCT05916560](https://clinicaltrials.gov/study/NCT05916560) | A Study of LY3437943 in Participants With Impaired and Normal Liver Function | Healthy, Hepatic Insufficiency | Phase 1 | COMPLETED | 43 | | [NCT07232719](https://clinicaltrials.gov/study/NCT07232719) | A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | Obesity, Overweight | Phase 3 | ACTIVE_NOT_RECRUITING | 250 | | [NCT06808802](https://clinicaltrials.gov/study/NCT06808802) | To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants | Healthy | Phase 1 | COMPLETED | 30 | | [NCT06859268](https://clinicaltrials.gov/study/NCT06859268) | A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity | Obesity | Phase 3 | ACTIVE_NOT_RECRUITING | 643 | | [NCT05959096](https://clinicaltrials.gov/study/NCT05959096) | A Study of LY3437943 in Healthy Participants With a High Body Mass Index | Healthy | Phase 1 | COMPLETED | 85 | | [NCT05548231](https://clinicaltrials.gov/study/NCT05548231) | A Study of LY3437943 in Chinese Participants With Obesity Or Overweight | Overweight, Obesity | Phase 1 | COMPLETED | 32 | | [NCT06982859](https://clinicaltrials.gov/study/NCT06982859) | A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus | Diabetes Mellitus, Insulin Sensitivity | Phase 1 | ACTIVE_NOT_RECRUITING | 95 | | [NCT06039826](https://clinicaltrials.gov/study/NCT06039826) | A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese | Overweight | Phase 1 | COMPLETED | 46 | | [NCT06297603](https://clinicaltrials.gov/study/NCT06297603) | Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) | Type 2 Diabetes | Phase 3 | ACTIVE_NOT_RECRUITING | 320 | | [NCT05936151](https://clinicaltrials.gov/study/NCT05936151) | A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes | Overweight or Obesity, CKD | Phase 2 | COMPLETED | 146 | | [NCT06354660](https://clinicaltrials.gov/study/NCT06354660) | Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) | Diabetes Type 2 | Phase 3 | COMPLETED | 537 | | [NCT05929066](https://clinicaltrials.gov/study/NCT05929066) | A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight | Obesity, Overweight | Phase 3 | COMPLETED | 2335 | | [NCT04823208](https://clinicaltrials.gov/study/NCT04823208) | A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM) | Diabetes Mellitus, Type 2 | Phase 1 | COMPLETED | 64 | | [NCT07357415](https://clinicaltrials.gov/study/NCT07357415) | A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight | Obesity, Overweight | Phase 3 | ACTIVE_NOT_RECRUITING | 600 | | [NCT04881760](https://clinicaltrials.gov/study/NCT04881760) | A Study of LY3437943 in Participants Who Have Obesity or Are Overweight | Obesity, Overweight | Phase 2 | COMPLETED | 338 | | [NCT06982846](https://clinicaltrials.gov/study/NCT06982846) | A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia | Type 2 Diabetes Mellitus | Phase 1 | COMPLETED | 80 | ## Common questions **How many human trials does Retatrutide have?** 33, each listed above with a link to its original record. **Is Retatrutide FDA approved?** No. It is not approved by the FDA for any indication. **Where does this data come from?** ClinicalTrials.gov. We count interventional human studies only. Every trial links to its original record. --- *Automated aggregation from public registries. Not medical advice. No physician has reviewed this page. Source: https://www.whatsactuallyknown.com/compounds/retatrutide*